Review
doi: 10.1016/s0889-8588(05)70096-4.
Nasopharyngeal cancer
Affiliations
- PMID: 10494517
- DOI: 10.1016/s0889-8588(05)70096-4
Item in Clipboard
Review
Nasopharyngeal cancer
Hematol Oncol Clin North Am.
1999 Aug.
Abstract
The current standards of treatment for nasopharyngeal cancer include 1. In early disease (stage I and stage II), radiotherapy is the treatment of choice, and the chance for cure is usually high. 2. In locally advanced disease (stage III and stage IV) combination chemotherapy and radiation therapy is indicated. Further clinical trials are warranted, which may include the newer active chemotherapeutic agents. 3. Patients with distant metastases may be treated with chemotherapy alone or other palliative measures.
Similar articles
-
Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.Head Neck. 2003 Jul;25(7):585-94. doi: 10.1002/hed.10242. Head Neck. 2003. PMID: 12808662
-
Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.J Clin Oncol. 2005 Sep 20;23(27):6730-8. doi: 10.1200/JCO.2005.16.790. J Clin Oncol. 2005. PMID: 16170180 Clinical Trial.
-
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.Lancet Oncol. 2012 Feb;13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5. Epub 2011 Dec 7. Lancet Oncol. 2012. PMID: 22154591 Clinical Trial.
-
Chemotherapy in advanced nasopharyngeal cancer.Oncology (Williston Park). 2000 Aug;14(8):1223-30; discussion 1232-7, 1239-42. Oncology (Williston Park). 2000. PMID: 10989829 Review.
-
Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.Cancer Treat Rev. 2009 Jun;35(4):345-53. doi: 10.1016/j.ctrv.2009.01.002. Epub 2009 Feb 10. Cancer Treat Rev. 2009. PMID: 19211192 Review.
Cited by
-
Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma.Clin Exp Metastasis. 2012 Dec;29(8):865-77. doi: 10.1007/s10585-012-9465-5. Epub 2012 Jun 17. Clin Exp Metastasis. 2012. PMID: 22706927
-
Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma: a 10-year experience.Ann Surg Oncol. 2011 Jan;18(1):233-8. doi: 10.1245/s10434-010-1292-9. Epub 2010 Aug 25. Ann Surg Oncol. 2011. PMID: 20737217 Free PMC article.
-
Prognostic value of tumor volume in nasopharyngeal carcinoma.Yonsei Med J. 2005 Apr 30;46(2):221-7. doi: 10.3349/ymj.2005.46.2.221. Yonsei Med J. 2005. PMID: 15861494 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
